The National Academy of Clinical Biochemistry's (NACB) Laboratory Medicine Practice Guidelines (LMPG) for use of cardiac markers in coronary artery diseases were published in July 1999 1 . Since production of this initial document, numerous published studies and presented data have added significantly to the knowledge base for biochemical markers of cardiac injury. This increased knowledge has substantially expanded the scope of recommendations for biochemical marker utilization since the 1999 document, and in particular has required the inclusion of recommendations regarding biochemical markers that extend beyond myocardial necrosis. Toward addressing these advances and their impact on biochemical marker utilization in clinical practice, the NACB appointed a chair and members of an LMPG committee that was charged with revising and extending the earlier recommendations by establishing modern guidelines The strength of scientific data supporting each recommendation is characterized using the scoring criteria adopted from the American Heart Association/American College of Cardiology as summarized in Table 1 . For each recommendation, the designations I, IIa, IIb, and III describe the indications, and the upper-case letters A through C describe the weight of evidence. Levels of evidence listed in the guidelines were determined by the full writing committee. Ratings were discussed in detail until consensus of the full writing committee was reached. There was no process for recusal. The members of the committee have reported all relevant relationships with industry to be published with these guidelines.
These guidelines were developed utilizing best available evidence, and they incorporated substantial input from Level of Evidence C Expert consensus was the primary basis for the recommendation.
acknowledged experts and professional organizations. As such, they represent the current best practice for utilization of biochemical markers of cardiac injury.
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